



OPEN ACCESS

EDITED BY
Chandrima Das,
Saha Institute of Nuclear Physics (SINP),
India

REVIEWED BY
Salvatore Saccone,
University of Catania, Italy
Manuel Serrano,
Institute for Research in Biomedicine,
Spain

*CORRESPONDENCE
Umer Farooq,
umerf@ncbs.res.in
Dimple Notani,
dnotani@ncbs.res.in

SPECIALTY SECTION
This article was submitted to
Epigenomics and Epigenetics,
a section of the journal
Frontiers in Cell and Developmental
Biology

RECEIVED 19 May 2022
ACCEPTED 09 August 2022
PUBLISHED 09 September 2022

CITATION
Farooq U and Notani D (2022),
Transcriptional regulation of INK4/ARF
locus by cis and trans mechanisms.
Front. Cell Dev. Biol. 10:948351.
doi: 10.3389/fcell.2022.948351

COPYRIGHT
© 2022 Farooq and Notani. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Transcriptional regulation of INK4/ARF locus by cis and trans mechanisms

Umer Farooq^{1,2*} and Dimple Notani^{1*}

¹Genetics and Development, National Centre for Biological Sciences, Tata Institute for Fundamental Research, Bangalore, India, ²The University of Trans-Disciplinary Health Sciences and Technology, Bangalore, India

9p21 locus is one of the most reproducible regions in genome-wide association studies (GWAS). The region harbors *CDKN2A/B* genes that code for p16^{INK4a}, p15^{INK4b}, and p14^{ARF} proteins, and it also harbors a long gene desert adjacent to these genes. The polymorphisms that are associated with several diseases and cancers are present in these genes and the gene desert region. These proteins are critical cell cycle regulators whose transcriptional dysregulation is strongly linked with cellular regeneration, stemness, aging, and cancers. Given the importance of this locus, intense scientific efforts on understanding the regulation of these genes via promoter-driven mechanisms and recently, via the distal regulatory mechanism have provided major insights. In this review, we describe these mechanisms and propose the ways by which this locus can be targeted in pathologies and aging.

KEYWORDS

INK4/ARF, enhancer, 9p21, gene desert, p15^{INK4b}, p16^{INK4a}, ANRIL, CDKN2BAS

Introduction


The INK4/ARF locus functions are attributed to three distinct but related proteins, namely, p14^{ARF}, p16^{INK4a}, and p15^{INK4b}. These proteins are coded by two genes; *CDKN2A* and *CDKN2B*. p14^{ARF} and p16^{INK4a} are transcribed from the *CDKN2A* gene, whereas p15^{INK4b} is transcribed from the *CDKN2B* gene (Figure 1). The initial exons of p14^{ARF} (exon1 β) and p16^{INK4a} (exon1 α) are different, but the second and third exons are identical. While the mRNA sequences of p14^{ARF} and p16^{INK4a} are relatively similar, the resultant proteins do not share any sequence similarity due to the alternative reading frames; thus, these proteins are not isoforms. On the other hand, p15^{INK4b} and p16^{INK4a} have a high degree of amino acid similarity (about 80%) and are thought to have emerged from a gene duplication event (Lopez et al., 2017). Additionally, there is a *CDKN2BAS* gene that transcribes a non-coding RNA known as ANRIL. Because ANRIL is transcribed in the antisense direction relative to *CDKN2B*, the gene is termed *CDKN2BAS*. Together, these proteins regulate the cell cycle progression and are known to operate as a barrier to the reprogramming of somatic cells. Inactivation of this locus due to homozygous deletions or epigenetic alterations such as transcriptional silencing by DNA methylation or polycomb-mediated suppression is a frequent event that occurs in a wide spectrum of


cancers. Furthermore, single nucleotide polymorphisms (SNPs) in this locus are associated with several aging-related disorders, including coronary artery disease (CAD), type 2 diabetes, and atherosclerosis. The majority of the SNPs in this locus are located within the genes and the ~0.3 Mb long adjacent gene desert region, but the mechanisms of their action are largely unknown. Thus, the identification of molecular pathways that regulate this locus in different diseases is of great therapeutic relevance.

Cell cycle regulation by INK4/ARF proteins

Several stress signals including oncogene overexpression, DNA damage, oxidative stress, etc., induce the expression of *INK4/ARF* genes (Romagosa et al., 2011). Once activated, these genes trigger a cascade of signaling events that effectively bring the cell cycle to a halt (Ivanchuk et al., 2001). Mechanistically, p53 (a well-studied tumor suppressor that blocks the cell cycle at

the G1 phase) is a downstream effector of the p14^{ARF} pathway (Sherr 2001). The interaction of MDM2 with p53 alters the stability and cellular localization of p53 (Kubbutat, Jones, and Vousden 1997). MDM2 acts as an E3 ubiquitin ligase and mediates the proteasomal degradation of p53 by ubiquitinating its C-terminal domain (Wade, Wang, and Wahl 2010). Multiple domains of p53 interact with MDM2, including the DNA binding domain (DBD), the transactivation domain (TAD), and the carboxy-terminal domain (CTD). MDM2, on the other hand, interacts with p53 via its N-terminal hydrophobic domain (HD) and acid domain (AD) (Chi et al., 2005; Yu et al., 2006; Poyurovsky et al., 2010). When expressed, p14^{ARF} interacts with the acid domain of MDM2, preventing it from interacting with p53. This interaction alters the conformation of MDM2 that exposes its Nucleolar localization signal (NoLS) present in the RING domain (RD), leading to sequestration of the MDM2-p14^{ARF} complex in the nucleolus (Weber et al., 1999; Maggi et al., 2014). Sequestration of MDM2 in the nucleolus prevents MDM2-mediated export of p53 to the cytoplasm, hence preventing its degradation (Maggi





et al., 2014). These events lead to p53 translocation into the nucleus thereby, activating genes that cause the cell cycle to arrest at the G1 phase (Weber et al., 1999) (Figure 2A).

p16^{INK4a} and p15^{INK4b}, on the other hand, regulate the retinoblastoma (Rb) pathway. These proteins activate Rb, a tumor suppressor protein that blocks the cell cycle at the G1 phase (Kim and Sharpless 2006). CDK4/6 typically forms an active complex with cyclin D that binds to and phosphorylates Rb (Cobrinik 2005). Rb loses its ability to interact with the E2F transcription factor in the phosphorylated state (Dimova and Dyson 2005). E2F activates genes involved in the cell cycle transition from G1 to S (Giacinti and Giordano 2006). When stress signals activate p16^{INK4a}/p15^{INK4b}, these proteins bind to CDK4/CDK6, causing an allosteric shift in the latter proteins, preventing them from forming the active complex with cyclin D, thereby maintaining Rb in a hypophosphorylated state (Hannon and Beach 1994; Russo et al., 1998). Hypophosphorylated Rb binds with the transactivation domain of E2; this complex subsequently recruits HDAC1 and SUV39H1 to the E2F target genes, thereby inhibiting them and preventing the G1 to S phase transition (Giacinti and Giordano 2006) (Figure 2B). These proteins being high in cellular senescence, permanently inhibit cell division. However, HPV-positive cancer cells express significant levels of p16^{INK4a}, p14^{ARF}, and p15^{INK4b} without undergoing cell cycle arrest, attributed to two

HPV-encoded oncoproteins, E6 and E7 (Kanao et al., 2004). These proteins inhibit the downstream effectors of p14^{ARF} and p16^{INK4a} genes, thereby preventing cell cycle arrest. E7 interacts with Rb, leading to its inactivation, whereas E6 induces the degradation of p53 protein (Munger et al., 1992).

Implication of INK4/ARF locus in aging, cancer, and regeneration

INK4/ARF locus in senescence/aging

Senescence is an innate cellular response in which normally proliferating cells cease to divide permanently in response to specific intrinsic and extrinsic stimuli. Senescent cells exhibit morphological and physiological changes, the formation of senescence-associated heterochromatin foci (SAHF), and the release of senescence-associated secretory phenotype (SASP), etc., (van Deursen 2014). This irreversible cell cycle halt is thought to be the first line of defense against cancer by preventing the division of abnormal cells (Prieto and Baker 2019). Senescence, on the other hand, plays a significant role in aging-related pathologies, as it impairs tissue repair and regeneration (McHugh and Gil 2018). Several recent studies have expanded our understanding of the role of senescence in other complex biological processes such as development, and

tissue repair, among others (Herranz and Gil 2018). p16^{INK4a} is the fundamental driver and a well-established biomarker of senescence (Krishnamurthy et al., 2004; Rayess, Wang, and Srivatsan 2012). Studies have demonstrated that ectopic expression of oncogenes like Ras and Raf, increases p16^{INK4a} expression, triggering premature senescence in various cell types (Lin et al., 1998; Zhu et al., 1998). For example, fibroblasts, epithelial cells, and T lymphocytes, express higher p16^{INK4a} when they approach replicative senescence (Lin et al., 1998; Zhu et al., 1998; Mirzayans et al., 2012). In summary, the INK4/ARF locus regulates oncogene-induced and replicative senescence in several cell types (Mirzayans et al., 2012).

INK4/ARF locus in cancer

Cancer cells proliferate abnormally and do not respond to signals that regulate cell growth and division. Most frequently, cancer cells contain mutations in genes that regulate the cell cycle; once altered, these genes lose their ability to control the cell cycle (Papp and Plath 2011). As mentioned previously, *INK4/ARF* genes are cell cycle regulators that arrest the cell cycle at various stages in response to stress signals such as DNA damage. These tumor suppressor genes must be silenced for cancer to progress. Thus, INK4/ARF locus harbors homozygous deletions in several malignancies, silencing the expression of all three cell cycle regulator genes (Sherr 2012). Similarly, loss of p16^{INK4a} expression through specific point mutations has been reported in several cancers (Forbes et al., 2006). The suppression of this locus by DNA hypermethylation at the promoters or through histone modifications mediated by the PRC2 complex is also prevalent in cancers. In animal studies, mice lacking either *INK4a* or *ARF* gene are more susceptible to certain tumors than mice lacking the *INK4b* gene. On the other hand, overexpression of the *INK4/ARF* genes results in a threefold reduction in tumor incidence in mice (Matheu et al., 2004).

INK4/ARF locus in cellular reprogramming

Cellular plasticity facilitates the reprogramming of somatic cells to a more pluripotent state. This reprogramming process considerably alters the epigenetic and chromatin landscapes of the cells (Papp and Plath 2011). A few critical transcription factors, like Oct4, Sox2, Klf4, Nanog, and others, can transform a somatic cell into a pluripotent cell (Papp and Plath 2011). However, the primary limitation of reprogramming is its significantly lower efficiency (approx. 1%). In the fast-dividing embryonic stem cells and induced pluripotent stem cells (iPSCs), the INK4/ARF locus is repressed. This locus, however, is activated

during the reprogramming process as a result of highly mitogenic cell culture conditions (Sharpless 2005). As a result of the activation of this locus in somatic cells, reprogramming efficiency decreases significantly. Conversely, mouse embryonic fibroblasts (MEFs) lacking the INK4/ARF locus reprogram more efficiently with 15-fold higher efficiency (Li et al., 2009). While silencing *INK4a* or *ARF* alone improves reprogramming efficiency, double silencing results in increased efficiency, as seen in *INK4/ARF* null cell lines (Li et al., 2009). Not only is the efficiency increased, but the rate at which iPSC colonies develop is also increased in *INK4/ARF* defective cells. Interestingly, *ARF* is the primary regulator of cell reprogramming in murine cells, but *INK4a* is the dominant regulator in humans (Li et al., 2009).

Transcriptional regulation of INK4/ARF locus

Repression of INK4/ARF locus via PRC complexes

Polycomb group (PcG) proteins are epigenetic modifiers that play a crucial role in transcriptional repression and therefore regulate cell proliferation, differentiation, embryonic development, cellular memory, and other vital cellular functions (Wang et al., 2015). PcGs form two major protein complexes, the Polycomb repressive complex 1 (PRC1) and the Polycomb repressive complex 2 (PRC2). PRC2 exerts inhibition by adding trimethyl marks to lysine 27 of histone 3 (H3K27me3). The trimethyl mark serves as a docking site for PRC1, which recognizes this mark and monoubiquitinates Histone 2A at lysine 119 (H2AK119ub) (Chittock et al., 2017). The H2AK119ub further enhances H3K27me3 deposition by PRC2 and subsequent recruitment of PRC1 (Chittock et al., 2017). Both PRC1 and PRC2 are multimeric protein complexes with several core subunits and a few auxiliary subunits (Kerppola 2009). The PRC1 core consists of RING1A/B, PCGF2/4, CBX2/4/6/7/8, PHC1/2/3 subunits, while PRC2 contains Suz12, Ezh2, RbAp46/48, and Eed as core subunits (Chittock et al., 2017). Additionally, various auxiliary subunits aid or improve the activity of these complexes (Chittock et al., 2017). Ezh2, a SET domain-containing protein, is the enzymatic component of the PRC2 complex responsible for the trimethylation of H3K27. At the INK4/ARF locus, PcG inhibits the promoters by trimethylating H3K27 to increase cell proliferation (Bracken et al., 2007). PcGs have been demonstrated to repress all three *INK4a*, *ARF*, and *INK4b* genes in some instances, but only *INK4a* and *INK4b* in others (Bruggeman et al., 2005; Bracken et al., 2007; Kheradmand Kia et al., 2009). Ectopic expression of PcG subunits such as Bmi1, Ezh2, CBX7, and CBX8 has been shown to downregulate *INK4a* and *INK4b* expression to

bypass senescence (Jacobs et al., 1999; Gil et al., 2004; Dietrich et al., 2007). In contrast, depletion of the PcG subunits activates this locus, resulting in cell growth inhibition and senescence (Bracken et al., 2007; Dietrich et al., 2007).

Several transcription factors facilitate PcG binding to *INK4/ARF* promoters; for example, Zfp277, a zinc finger protein, interacts with the Bm1 subunit of PRC1 to recruit PRC1 to these promoters in MEFs (Negishi et al., 2010). Zfp277 depletion causes the PRC1 complex to displace from the promoters, activating *INK4a/ARF* gene and early senescence (Negishi et al., 2010). Similarly, Homeobox proteins such as HLX1 and HOXA9 play an essential role in suppressing *INK4a*. These proteins cooperate with PRC2 and HDACs at the *INK4a* promoter to mediate the repression (Martin et al., 2013). Haematopoietically expressed homeobox gene (*Hhex*) is vital in maintaining acute myeloid leukemia (AML), as its deletion causes upregulation of *INK4a* and *ARF*. Further, *Hhex*, like HLX1 and HOXA9, facilitates PRC2 binding to the promoters by interacting with the Suz12 subunit, thereby repressing the genes (Shields et al., 2016). In neonatal human diploid fibroblasts (HDFs), PRC2 binding to the *INK4a* promoter and the upstream region of the *INK4b* promoter induces a long-range interaction (repressive chromatin loop) between these promoters (Kheradmand Kia et al., 2009). Similar long-range interaction between the *INK4a* and *INK4b* promoters has been observed in hematopoietic progenitor cells and malignant rhabdoid tumors (MRTs) (Kheradmand Kia et al., 2009). In mature HDFs, however, the chromatin architecture of these genes is noticeably different where the looping between *INK4a* and *INK4b* is lost. Under such alterations, transcriptional activation and senescence induction occurs due to the concomitant loss of Ezh2 binding on promoters (Kheradmand Kia et al., 2009).


JMJD3-mediated transcriptional activation of *INK4/ARF* locus

Jumonji domain-containing D3 protein (JMJD3) is a lysine-specific histone demethylase. Its role in development, cancer progression, infectious diseases, immune disorders, and other conditions has been extensively studied (Xiang et al., 2007; Zhang X et al., 2019). JMJD3 belongs to the Jumonji (JmjC) domain-containing protein family, and this domain enzymatically catalyzes the removal of trimethyl marks from Histone 3 at lysine 27 (H3K27me3). Ubiquitously transcribed TPR protein on the X chromosome (UTX) is another demethylase that also demethylates H3K27me3 (Agger et al., 2007). While UTX is ubiquitously expressed, JMJD3 is induced in response to certain signaling events such as stress, etc (Swigut and Wysocka 2007). Due to its antagonistic role relative to PcG proteins, JMJD3 is a positive regulator of the *INK4/ARF*

during the onset of cellular senescence (Agger et al., 2009; Barradas et al., 2009). Many cellular signals have been implicated in the induction of JMJD3 expression and subsequent activation of the *INK4/ARF* genes. For example, oncogene-mediated upregulation of JMJD3 causes activation of *INK4/ARF* genes in various cell types like fetal lung fibroblasts (IMR90), MEFs, etc., which results in *INK4a*-mediated growth arrest in these cells (Agger et al., 2009). By activating the *INK4/ARF* locus, JMJD3 prevents Schwann cells from proliferating uncontrollably in response to tumorigenic signals or following injury (Gomez-Sanchez et al., 2013). Under these conditions, JMJD3 binds to and demethylates the *INK4/ARF* promoters, activating these genes and initiating senescence. These cells lose the cell cycle control and continue to proliferate, resulting in neurofibromas when this pathway is disturbed (Gomez-Sanchez et al., 2013). As mentioned in previous section, *INK4/ARF* locus functions as a barrier to MEFs and keratinocyte reprogramming, and its silencing enhances reprogramming efficiency (Li et al., 2009). JMJD3 increases p16^{INK4a} and p14^{ARF} expression, limiting MEF reprogramming (Zhao et al., 2013). Therefore, JMJD3 silencing inhibits *INK4/ARF*-mediated cellular senescence, improving reprogramming efficiency. Moreover, double knockdown of JMJD3 and *INK4a* or *ARF* further enhances the reprogramming efficiency (Zhao et al., 2013).

KDM2B-mediated transcriptional repression of *INK4/ARF* locus

KDM2B is an epigenetic modifier that preferentially demethylates trimethylated lysine 4 (H3K4me3) and dimethylated lysine 36 of histone H3 (H3K36me2) (Frescas et al., 2007). It regulates numerous biological processes, including cellular senescence, differentiation, and stem cell self-renewal (He et al., 2008; Liang et al., 2012; He et al., 2013). Furthermore, it is highly expressed in various cancers and plays a crucial role in cancer progression, especially in leukemia (Yan et al., 2018). KDM2B associates with the promoters of the *INK4/ARF* genes and demethylates histones H3K36me2 and H3K4me3. Demethylation results in a decrease in PolII binding and an increase in H3K27me3. KDM2B suppresses this locus by epigenetic modifications of histones and also by preventing the downregulation of Ezh2 (Tzatsos et al., 2009). Consequently, KDM2B protects MEFs from replicative and oncogenic senescence, and its knockdown decreases proliferation and induces senescence. Another study showed that KDM2B functions as a proto-oncogene and inhibits senescence by negatively regulating *INK4b*. Similarly, KDM2B achieves repression of *INK4b* by removing the active H3K36me2 mark near the promoter and the gene body, whereas its knockdown causes increased expression of *INK4b* (He et al., 2008).



DNA methylation-mediated transcriptional repression of INK4/ARF locus

In addition to the aforementioned mechanisms, DNA methylation is another epigenetic mechanism to silence *INK4/ARF* genes. DNA methylation is catalyzed by DNA methyltransferases (Dnmts), which transfer the methyl group from S-adenosyl methionine (SAM) to carbon 5 of cytosine to generate 5-methylcytosine (5mC) (Lyko 2018). CpG islands in the promoters of tumor suppressor genes undergo abnormal hypermethylation in cancers (Robertson and Jones 1998). Notably, *INK4a* was one of the first genes discovered to be silenced in human cancers as a result of DNA methylation (Esteller et al., 2001). Numerous malignancies have been linked to aberrant CpG island methylation in the promoter region of the *INK4/ARF* genes. CpG islands are present near the promoter of *ARF* and exon 1α of *INK4a* (Robertson and Jones 1998). Aberrant methylation of the *ARF* promoter is more prevalent than *INK4a* (Dominguez et al., 2003). Numerous types of cancer, including colon cancer, Merkel cell carcinoma, breast cancer, bladder tumors, and oligodendrogliomas, harbor abnormal DNA methylation of

these genes (Watanabe et al., 2001; Tsujimoto et al., 2002; Lee et al., 2006; Lassacher et al., 2008).

Chromatin remodelling of INK4/ARF locus via SWI/SNF complex

SWI/SNF is a multi-subunit ATP-dependent complex. This complex is largely involved in chromatin remodelling, which facilitates gene transcription by allowing transcription factors to access their DNA binding sites (Wilson and Roberts 2011). Abnormal expression and mutations in the SWI/SNF components can cause cancer (Klochendler-Yeivin, Muchardt, and Yaniv 2002; Orlando et al., 2019). Malignant rhabdoid tumors (MRTs) exhibit the loss of the hSNF5 gene, which encodes one of the subunits of the SWI/SNF complex (Biegel et al., 1999; Sevenet et al., 1999; Roberts and Orkin 2004). On the other hand, ectopic expression of hSNF5 inhibits cell growth and induces cellular senescence (Oruetebarria et al., 2004). It was found that hSNF5 exerts these effects via the p16^{INK4a}/Rb pathway, as the re-expression of hSNF5 in MRT cells activated *INK4b* and *INK4a*, but not *ARF* (Chai et al., 2005; Kia et al., 2008). hSNF5 activates *INK4a* in these cells by

recruiting the SWI/SNF complex to its promoter. As a result of its recruitment, the PRC1 and PRC2 complexes are displaced from the promoter (Kia et al., 2008).

Transcription factors involved in the regulation of *INK4/ARF* locus

Many transcription factors have been implicated in the regulation of the *INK4/ARF* locus. The majority of these transcription factors have been shown to act directly on the promoters of these genes. A few of them have been found to operate via upstream enhancer elements. While several transcription factors are required for the activation of the *INK4/ARF* genes, some have been demonstrated to inhibit their transcription (Figure 3). Due to the limited scope of this review, we have described only a few transcription factors involved in the activation of this locus.

FOXO1. FOXO1 is a tumor suppressor protein that inhibits Myc-induced lymphomagenesis in mice by activating the *ARF* gene. FOXO1 directly regulates *ARF* expression by binding to a motif located in the intron between exon1 β and exon1 α (Bouchard et al., 2007).

ZRF1. Zuotin-related factor 1 (ZRF1), a ubiquitin recognition domain-containing transcription factor, promotes the expression of PRC1-repressed genes during differentiation by competing for H2AK119Ub with PRC1 (Richly et al., 2010). ZRF1 expression is enhanced in MEFs and is recruited to the *INK4/ARF* promoters following hRas overexpression. Ectopic expression of ZRF1 activates *INK4a* and *INK4b* in IMR90, but not ZRF1delUBD, showing that ZRF1 binding to H2AK119Ub is necessary for its recruitment during senescence. (Ribeiro et al., 2013).

Dmp1. The deletion of Dmp1, a well-characterized tumor suppressor, accelerates tumor growth in mice. It acts as a link between Ras/Raf overexpression and *INK4/ARF* gene activation. Dmp1 expression is promoted by Ras overexpression, and it enhances *ARF* transcription by directly binding to Dmp1/ETS motif present in its promoter (Sreeramaneni et al., 2005).

JDP2. Jun dimerization protein 2 (JDP2) is a transcription factor that binds to JDP2 response regions and prevents histone acetylation and methylation (Huang et al., 2011). JDP2 is required for normal cell differentiation and proliferation, as MEFs lacking JDP2 do not undergo replicative senescence. Its overexpression inhibits MEF proliferation by increasing the expression of *INK4a* and *ARF* (Nakade et al., 2009).

CTCF. In U2OS cells, CTCF binds to a DNA sequence near the *ANRIL* promoter, and its silencing results in down-regulation of all three *INK4/ARF* genes. CTCF binding is lost when its DNA motif is methylated, resulting in the downregulation of these genes (Rodriguez et al., 2010).

CHD7. Chromodomain helicase DNA binding protein 7 (CHD7) is an ATP-dependent chromatin remodeler that plays


a critical role in Ras-mediated senescence. It is essential for the activation of *INK4a* following Ras overexpression (Su et al., 2018). Transcription factors like c-Jun and Ets1 promote Myeloid zinc finger 1 (MZF1) expression during Ras-induced senescence, which in turn recruits CHD7 to the promoter of *INK4a* for its upregulation (Wu et al., 2022).

HBP1. HMG box-containing protein 1 (HBP1) transcription factor is a downstream effector protein in the Ras signaling pathway. *INK4a* promoter contains a putative binding motif for this transcription factor between positions -426 and -433. Its binding to this motif triggers cellular senescence (Li et al., 2010). HBP1 promotes acetylation of the *INK4a* promoter by assisting in the recruitment of histone acetyltransferase p300 and CREB-binding protein (CBP) (Wang et al., 2012). Furthermore, ectopic expression of HBP1 induces premature cellular senescence in normal fibroblasts via *INK4a*, while its knockdown delays senescence and senescence-associated phenotypes (Wang et al., 2012).

SP1. *INK4a* promoter has numerous GC-rich regions that are required for its induction upon senescence onset (Wu et al., 2007). SP1, a transcription factor, with a strong affinity for GC-rich motifs binds to these regions to enhance *INK4a* expression. In human fibroblasts, ectopic expression of SP1 upregulates the *INK4a* (Wu et al., 2007). Furthermore, SP1, like HBP1 physically interacts with p300/CBP to promote *INK4a* expression. (Wang et al., 2008).

Transcriptional regulation of *INK4/ARF* locus by distal regulatory elements

As stated earlier, the gene desert region upstream of the *CDKN2A/B* genes contains several SNPs that are strongly associated with the risk of CAD and type 2 diabetes in humans. In mice, deletion of this CAD (70 kb) interval resulted in a substantial decrease in the cardiac expression of *CDKN2A/B* genes, significantly increased mortality upon high cholesterol diet and ARF-dependent developmental abnormalities (Visel et al., 2010). Primary cells isolated from such mice showed increased proliferation compared to wild-type cells and exhibited no signs of senescence over subsequent passages (Visel et al., 2010). Furthermore, allele-specific expression analysis in heterozygous mice carrying a CAD interval deletion on one chromosome revealed that the *cdkn2b* gene was preferentially expressed from the allele with a wild-type CAD interval, but the expression of the allele bearing the CAD deletion was dramatically reduced in the heart and other organs, implying that CAD interval may regulate these genes through a distant-acting cis-regulatory mechanism (Visel et al., 2010). Further work indicated that the mice lacking the CAD interval developed primary vitreous hyperplasia at the E13.5 developmental stage. It is well established that TGF β regulates *ARF* expression in developing eyes and MEFs




(Freeman-Anderson et al., 2009). It leads to *ARF* induction in MEFs and HeLa cells (Zheng et al., 2010).

In pursuit of understanding how this interval regulates the expression of *INK4/ARF* genes and to biologically underpin the genetic variations in the interval seen in several diseases, the interval was tested for the presence of distal regulatory elements known as enhancers. Towards this, a landmark study established the presence of several enhancers in the gene desert region of this locus (Harismendy et al., 2011). A relationship between the CAD-associated genetic variations (rs10811656 and rs10757278) in one of the enhancer elements (ECAD9) where STAT1 binds upon IFN γ stimulation was established. STAT1 binding on the homozygous CAD risk allele was reduced in lymphoblastoid cells (LCL) therefore, the knockdown of STAT1 in LCLs that were homozygous for the non-risk CAD allele upregulated *CDKN2BAS* suggesting a repressive role of STAT1 on *CDKN2BAS* expression. However, HUVEC cells exhibited an activatory role of STAT1 on the expression of *CDKN2BAS* suggesting, the effects of CAD risk allele on *INK4/ARF* genes could be cell-type specific (Harismendy et al., 2011). Notably, the CAD risk interval contains a cis-acting enhancer that collaborates with TGF β to promote *ARF* expression during development (Zheng et al., 2013), and mice lacking the CAD interval don't show such induction of *ARF*, implying that TGF β works on *ARF* via the enhancers in CAD interval. Furthermore, TGF β induces three H3K27ac peaks at the 110 kb distance from the *CDKN2A* promoter in HeLa cells and the deletion of a 20 kb area spanning all three peaks significantly lowers *ARF* and *INK4b* expression (Liu et al., 2019). These findings imply that TGF β affects the transcription of these genes by activating the enhancers upstream of the genes (Liu et al., 2019). Macrophages derived from mice with an atherosclerosis susceptibility

locus express significantly lower levels of *INK4a* and *ARF* (p19 in mice), but not *INK4b* (Kuo et al., 2011). Furthermore, individuals with the risk allele rs10757278, which has been related to an increased risk of atherosclerosis, have lower expression of all three *INK4/ARF* genes and even ANRIL in peripheral blood T-cells (Liu et al., 2009). Another study discovered a cis-regulatory region adjacent to the *ARF* promoter that represses *INK4a* gene expression. This element loops with the promoter of *INK4a* to repress its transcription. Perturbation of the element stimulated the transcription of the *INK4a* gene. (Zhang Y et al., 2019). All of these studies show a connection between disease-associated SNPs in the gene desert interval and *INK4/ARF* gene expression. Taken together, the risk alleles for CAD and atherosclerosis are primarily associated with lower expression of the *INK4/ARF* genes and these effects are cell-type specific.

Recently, we showed that the gene desert region upstream of the *INK4/ARF* genes contains 21 potential enhancer elements in the HeLa cells. Among these enhancers, 15 enhancers exhibited marks of active enhancers such as H3K27ac, PolII, and eRNA transcription. Out of these, only five active enhancers interacted with the *CDKN2A/B* gene promoters. However, disruption of any of these interacting enhancers but not non-interacting enhancer impacted the expression of *INK4a*, *ARF*, and *INK4b* at similar levels (Farooq et al., 2021). Interestingly, the interacting and non-interacting enhancers were indistinguishable at the levels of enhancer marks such as levels of H3K27ac, p300, and eRNA expression. This indicates that the bio-chemical marking of enhancers alone fails to predict enhancer activity (Farooq et al., 2021) (Figure 4). However, how SNPs in these enhancers regulate the locus in various diseases requires more efforts focused on functional studies to molecularly underpin the genetic variation and associated diseases in this locus. The



resultant mechanistic understanding will pave the way for future therapeutic interventions.

lncRNAs as transcriptional regulators of the INK4/ARF locus

Long noncoding RNAs (lncRNAs) are a subclass of RNAs that are longer than 200 nucleotides and do not code for any protein product. They play critical roles in gene regulation, chromatin organization, translational regulation, etc. Several lncRNAs have been reported to influence the INK4/ARF locus expression (Puvvula 2019). Most of them are repressive and act by recruiting the PcG complexes onto the promoters of these genes. Recently, certain lncRNAs have been described to activate this locus (Figure 5).

lncRNAs-mediated repression of INK4/ARF locus

INK4/ARF locus contains a lncRNA, ANRIL, which is transcribed antisense to the genes. ANRIL is ~3.8 kb and has over 20 different splice variants. These splice variants of ANRIL play a differential protective role depending on the presence or absence of CAD risk interval (Lo Sardo et al., 2018). ANRIL is required for INK4/ARF silencing in growing cells, as its expression in these cells is inversely correlated to gene expression (Yap et al., 2010; Kotake et al., 2011). This repression is a result of PRC2 loading on

the INK4a promoter by nascently transcribing ANRIL RNA (Yap et al., 2010). Another study demonstrated similar recruitment of PRC2 to the INK4b promoter (Kotake et al., 2011). Therefore, ANRIL expression decreases as senescence progresses for the activation of this locus. Through RNA binding experiments, ANRIL was shown to interact with the CBX7 component of PRC1 to enhance INK4/ARF gene silencing (Yap et al., 2010). Subsequently, ANRIL binding to SUZ12, a component of the PRC2 complex, was shown to enhance the silencing of INK4b, but not INK4a (Kotake et al., 2011). In contrast to these observations, ANRIL expression is positively linked with INK4a/ARF expression, in cervical cancers. In a recent study, we report that the PRC2 complex can bind to the INK4/ARF promoters independent of ANRIL levels in cervical cancer cell lines (Farooq et al., 2021). Another lncRNA, MIR31HG, which is transcribed from the short arm of chr9 itself, has been shown to recruit PRC complex on the INK4a promoter (Montes et al., 2015). Interestingly, during OIS (Oncogene induced senescence), MIR31HG localizes solely to the cytoplasm. This leads to the loss of the PRC complex from the INK4a promoter, resulting in transcriptional activation of INK4a (Montes et al., 2015). PANDAR (promoter of CDKN1A antisense DNA damage-activated RNA) is elevated in breast cancer tissues and cell lines. PANDAR interacts with Bmi1, a PRC1 subunit, inhibiting INK4a transcription by loading Bmi1 to its promoter. PANDAR silencing reduces cell proliferation and colony formation in MCF7 cells and causes G1/S arrest in a p16^{INK4a}-dependent manner (Sang et al., 2016). PVT1 is critical for gastric cancer progression. It accomplishes this in part by forming a complex with EZH2 and directing it to the promoters of INK4b and INK4a,

suppressing their expression in gastric cancer (Kong et al., 2015). ANROC, a recently discovered lncRNA, is found downstream of the *INK4a* gene, and its silencing results in overexpression of all three genes, indicating that ANROC is a repressive RNA (Kotake and Tsuruda 2020).

LncRNAs-mediated activation of *INK4/ARF* locus

LncRNA ARHGAP27P1 is downregulated in gastric cancer cells, and when overexpressed, it inhibits gastric cancer cell proliferation, migration, and other functions in a p16^{INK4a} and p15^{INK4b}-dependent manner. This lncRNA regulates *INK4/ARF* expression by interacting with and directing the histone demethylase JMJD3 to the promoters for removal of the repressing H3K27me3 mark (Zhang G et al., 2019). AUF1 is an RNA-binding lncRNA that has been found to enhance the degradation of various RNAs. P14AS was identified using RNA capture sequencing as a novel RNA with its promoter located on the antisense strand of the fragment near *CDKN2A* exon1 β . P14AS binds to AUF1, preventing ANRIL/*INK4a* RNA from interacting with AUF1. This competitive interaction between P14AS and AUF1 promotes *ARF*, *INK4b*, and *INK4a* gene expression (Ma et al., 2020). During OIS, VAD (Vlinc RNA Antisense to DDAH1) is highly upregulated and required to maintain senescence characteristics. VAD functions in trans on the *INK4/ARF* locus, and its depletion causes downregulation of *ARF*, *INK4b*, and *INK4a*. VAD promotes the expression of these genes by removing H2A.Z from their promoters. H2A.Z deposition represses these genes by promoting the recruitment of the PRC complex to the promoters (Lazorthes et al., 2015). Several circular ANRIL isoforms have been identified that activate the *INK4/ARF* genes rather than inhibiting them. They switch from repressors to activators of these genes during RAF1-mediated senescence. These circular isoforms engage with Polycomb subunits and displace EZH2 from the *INK4b* and *INK4a* promoters, stimulating transcription of these genes. As a result of the PRC2 dislocation, H3K27me3 levels at these promoters drop (Muniz et al., 2021). Similarly, TUBA4b is downregulated in CRC tissues and cells, and its overexpression inhibits CRC cell proliferation by upregulating *INK4a* and *INK4b* (Zhou, Sun, and Zhou 2020). The precise mechanisms by which TUBA4b long noncoding RNA activates these genes are unknown.

Discussion

Since the products of the *INK4/ARF* genes are implicated in a wide range of cancers and age-related diseases, they hold immense promise for treating or mitigating the consequences of these diseases. Regulation of the *INK4/ARF* locus is multi-layered, with a plethora of factors involved. As a result, the greatest challenge in harnessing this locus for therapeutic

purposes is identifying the critical regulatory elements that can be targeted in a particular disease. Targeting transcription factors or epigenetic modifiers involved in its regulation has very broad effects, affecting not just this locus but others as well. We recently uncovered a few enhancers in the upstream enhancer cluster that regulate these genes. These DNA regulatory elements can be altered to provide a more precise and targeted effect. Since this enhancer cluster contains multiple enhancers, these enhancers may act in a tissue type-specific manner. Thus, determining which enhancers regulate these genes under various physiological conditions is critical for the therapeutic use of enhancers or enhancer products like eRNAs. Additionally, SNPs in upstream enhancer regions have been associated with several diseases. These SNPs can facilitate the identification of regulatory enhancers in various cell types. Thus, a functional genomics approach is required to decipher how these SNPs result in changes in gene regulation.

Author contributions

UF and DN have prepared the manuscript.

Acknowledgments

We thank members of DN lab for discussion and suggestions. We thank Sudha Swaminathan and Salsabeel Khan for critical comments on review. DN acknowledges funding support from, India-Alliance DBT-Wellcome (IA: IA/1/14/2/501539), SERB (CRG/2019/005714). Department of Atomic Energy, Government of India, under project no.12-R&D-TFR-5.04-0800 and intramural funds from NCBS-TIFR. DN also acknowledges support from EMBO global investigator program. UF is supported by the fellowship from CSIR, India.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Agger, K., Cloos, P. A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., et al. (2007). UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. *Nature* 449, 731–734. doi:10.1038/nature06145
- Agger, K., Cloos, P. A., Rudkjaer, L., Williams, K., Andersen, G., Christensen, J., et al. (2009). The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. *Genes Dev.* 23, 1171–1176. doi:10.1101/gad.510809
- Barradas, M., Anderton, E., Acosta, J. C., Li, S., Banito, A., Rodriguez-Niedenfuhr, M., et al. (2009). Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. *Genes Dev.* 23, 1177–1182. doi:10.1101/gad.511109
- Biegel, J. A., Zhou, J. Y., Rorke, L. B., Stenstrom, C., Wainwright, L. M., and Fogelgren, B. (1999). Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. *Cancer Res.* 59, 74–79.
- Bouchard, C., Lee, S., Paulus-Hock, V., Loddenkemper, C., Eilers, M., and Schmitt, C. A. (2007). FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. *Genes Dev.* 21, 2775–2787. doi:10.1101/gad.453107
- Bracken, A. P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., et al. (2007). The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. *Genes Dev.* 21, 525–530. doi:10.1101/gad.415507
- Bruggeman, S. W., Valk-Lingbeek, M. E., van der Stoop, P. P., Jacobs, J. J., Kieboom, K., Tanger, E., et al. (2005). Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. *Genes Dev.* 19, 1438–1443. doi:10.1101/gad.1299305
- Chai, J., Charboneau, A. L., Betz, B. L., and Weissman, B. E. (2005). Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. *Cancer Res.* 65, 10192–10198. doi:10.1158/0008-5472.CAN-05-1896
- Chi, S. W., Lee, S. H., Kim, D. H., Ahn, M. J., Kim, J. S., Woo, J. Y., et al. (2005). Structural details on mdm2-p53 interaction. *J. Biol. Chem.* 280, 38795–38802. doi:10.1074/jbc.M508578200
- Chittock, E. C., Latwiel, S., Miller, T. C., and Muller, C. W. (2017). Molecular architecture of polycomb repressive complexes. *Biochem. Soc. Trans.* 45, 193–205. doi:10.1042/BST20160173
- Cobrinik, D. (2005). Pocket proteins and cell cycle control. *Oncogene* 24, 2796–2809. doi:10.1038/sj.onc.1208619
- Dietrich, N., Bracken, A. P., Trinh, E., Schjerling, C. K., Koseki, H., Rappsilber, J., et al. (2007). Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. *EMBO J.* 26, 1637–1648. doi:10.1038/sj.emboj.7601632
- Dimova, D. K., and Dyson, N. J. (2005). The E2F transcriptional network: Old acquaintances with new faces. *Oncogene* 24, 2810–2826. doi:10.1038/sj.onc.1208612
- Dominguez, G., Silva, J., Garcia, J. M., Silva, J. M., Rodriguez, R., Munoz, C., et al. (2003). Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. *Mutat. Res.* 530, 9–17. doi:10.1016/s0027-5107(03)00133-7
- Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. (2001). A gene hypermethylation profile of human cancer. *Cancer Res.* 61, 3225–3229.
- Farooq, U., Saravanan, B., Islam, Z., Walavalkar, K., Singh, A. K., Jayani, R. S., et al. (2021). An interdependent network of functional enhancers regulates transcription and EZH2 loading at the INK4a/ARF locus. *Cell Rep.* 34, 108898. doi:10.1016/j.celrep.2021.108898
- Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., et al. (2006). COSMIC 2005. *Br. J. Cancer* 94, 318–322. doi:10.1038/sj.bjc.6602928
- Freeman-Anderson, N. E., Zheng, Y., McCalla-Martin, A. C., Treanor, L. M., Zhao, Y. D., Garfin, P. M., et al. (2009). Expression of the Arf tumor suppressor gene is controlled by Tgfbeta2 during development. *Development* 136, 2081–2089. doi:10.1242/dev.033548
- Frescas, D., Guardavaccaro, D., Bassermann, F., Koyama-Nasu, R., and Pagano, M. (2007). JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. *Nature* 450, 309–313. doi:10.1038/nature06255
- Giacinti, C., and Giordano, A. (2006). RB and cell cycle progression. *Oncogene* 25, 5220–5227. doi:10.1038/sj.onc.1209615
- Gil, J., Bernard, D., Martinez, D., and Beach, D. (2004). Polycomb CBX7 has a unifying role in cellular lifespan. *Nat. Cell Biol.* 6, 67–72. doi:10.1038/ncb1077
- Gomez-Sanchez, J. A., Gomis-Coloma, C., Morenilla-Palao, C., Peiro, G., Serra, E., Serrano, M., et al. (2013). Epigenetic induction of the Ink4a/Arf locus prevents Schwann cell overproliferation during nerve regeneration and after tumorigenic challenge. *Brain*. 136, 2262–2278. doi:10.1093/brain/awt130
- Hannon, G. J., and Beach, D. (1994). p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. *Nature* 371, 257–261. doi:10.1038/371257a0
- Harismendy, O., Notani, D., Song, X., Rahim, N. G., Tanasa, B., Heintzman, N., et al. (2011). 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. *Nature* 470, 264–268. doi:10.1038/nature09753
- He, J., Kallin, E. M., Tsukada, Y., and Zhang, Y. (2008). The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). *Nat. Struct. Mol. Biol.* 15, 1169–1175. doi:10.1038/nsmb.1499
- He, J., Shen, L., Wan, M., Taranova, O., Wu, H., and Zhang, Y. (2013). Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes. *Nat. Cell Biol.* 15, 373–384. doi:10.1038/ncb2702
- Herranz, N., and Gil, J. (2018). Mechanisms and functions of cellular senescence. *J. Clin. Invest.* 128, 1238–1246. doi:10.1172/JCI91518
- Huang, Y. C., Hasegawa, H., Wang, S. W., Ku, C. C., Lin, Y. C., Chiou, S. S., et al. (2011). Jun dimerization protein 2 controls senescence and differentiation via regulating histone modification. *J. Biomed. Biotechnol.*, 569034. doi:10.1155/2011/569034
- Ivanchuk, S. M., Mondal, S., Dirks, P. B., and Rutka, J. T. (2001). The INK4A/ARF locus: Role in cell cycle control and apoptosis and implications for glioma growth. *J. Neurooncol.* 51, 219–229. doi:10.1023/a:1010632309113
- Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A., and van Lohuizen, M. (1999). The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. *Nature* 397, 164–168. doi:10.1038/16476
- Kanao, H., Enomoto, T., Ueda, Y., Fujita, M., Nakashima, R., Ueno, Y., et al. (2004). Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer. *Cancer Lett.* 213, 31–37. doi:10.1016/j.canlet.2004.03.030
- Kerppola, T. K. (2009). Polycomb group complexes—many combinations, many functions. *Trends Cell Biol.* 19, 692–704. doi:10.1016/j.tcb.2009.10.001
- Kheradmand Kia, S., Solaimani Kartalaei, P., Farahbakhshian, E., Pourfarzad, F., von Lindern, M., and Verrijzer, C. P. (2009). EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. *Epigenetics Chromatin* 2, 16. doi:10.1186/1756-8935-2-16
- Kia, S. K., Gorski, M. M., Giannakopoulos, S., and Verrijzer, C. P. (2008). SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. *Mol. Cell Biol.* 28, 3457–3464. doi:10.1128/MCB.02019-07
- Kim, W. Y., and Sharpless, N. E. (2006). The regulation of INK4/ARF in cancer and aging. *Cell* 127, 265–275. doi:10.1016/j.cell.2006.10.003
- Klochender-Yeivin, A., Muchardt, C., and Yaniv, M. (2002). SWI/SNF chromatin remodeling and cancer. *Curr. Opin. Genet. Dev.* 12, 73–79. doi:10.1016/s0959-437x(01)00267-2
- Kong, R., Zhang, E. B., Yin, D. D., You, L. H., Xu, T. P., Chen, W. M., et al. (2015). Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. *Mol. Cancer* 14, 82. doi:10.1186/s12943-015-0355-8
- Kotake, Y., Nakagawa, T., Kitagawa, K., Suzuki, S., Liu, N., Kitagawa, M., et al. (2011). Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. *Oncogene* 30, 1956–1962. doi:10.1038/nc.2010.568
- Kotake, Y., and Tsuruda, T. (2020). Long noncoding RNA ANROC on the INK4 locus functions to suppress cell proliferation. *Cancer Genomics Proteomics* 17, 425–430. doi:10.21873/cgp.20201
- Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., et al. (2004). Ink4a/Arf expression is a biomarker of aging. *J. Clin. Invest.* 114, 1299–1307. doi:10.1172/JCI22475
- Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. *Nature* 387, 299–303. doi:10.1038/387299a0
- Kuo, C. L., Murphy, A. J., Sayers, S., Li, R., Yvan-Charvet, L., Davis, J. Z., et al. (2011). Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation. *Arterioscler. Thromb. Vasc. Biol.* 31, 2483–2492. doi:10.1161/ATVBAHA.111.234492
- Lassacher, A., Heitzer, E., Kerl, H., and Wolf, P. (2008). p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. *J. Invest. Dermatol.* 128, 1788–1796. doi:10.1038/sj.jid.5701256
- Lazorthes, S., C. Vallot, S. Briois, M. Aguirrebengoa, J.Y. Thuret, G. St Laurent, C. Rougeulle, P. Kapranov, C. Mann, D. Trouche, D. and E. Nicolas. 2015. A vlincRNA participates in senescence maintenance by relieving H2AZ-mediated repression at the INK4 locus. *Nat Commun.* 6: 5971.

- Lee, M., Sup Han, W., Kyoung Kim, O., Hee Sung, S., Sun Cho, M., Lee, S. N., et al. (2006). Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. *Pathol. Res. Pract.* 202, 415–424. doi:10.1016/j.prp.2005.11.011
- Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Canamero, M., et al. (2009). The Ink4/Arf locus is a barrier for iPSC cell reprogramming. *Nature* 460, 1136–1139. doi:10.1038/nature08290
- Li, H., Wang, W., Liu, X., Paulson, K. E., Yee, A. S., and Zhang, X. (2010). Transcriptional factor HBP1 targets P16(INK4A), upregulating its expression and consequently is involved in Ras-induced premature senescence. *Oncogene* 29, 5083–5094. doi:10.1038/ncr.2010.252
- Liang, G., He, J., and Zhang, Y. (2012). Kdm2b promotes induced pluripotent stem cell generation by facilitating gene activation early in reprogramming. *Nat. Cell Biol.* 14, 457–466. doi:10.1038/ncb2483
- Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., and Lowe, S. W. (1998). Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. *Genes Dev.* 12, 3008–3019. doi:10.1101/gad.12.19.3008
- Liu, Y., Yan, Sanoff, Hanna K., Cho, Hyunsoo, Burd, Christin E., Torrice, Chad, Mohlke, Karen L., et al. (2009). INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. *PLoS One* 4, e5027. doi:10.1371/journal.pone.0005027
- Liu, Y. T., Xu, L., Bennett, L., Hooks, J. C., Liu, J., Zhou, Q., et al. (2019). Identification of *de novo* enhancers activated by TGFβ to drive expression of CDKN2A and B in HeLa cells. *Mol. Cancer Res.* 17, 1854–1866. doi:10.1158/1541-7786.MCR-19-0289
- Lo Sardo, V., Chubukov, P., Ferguson, W., Kumar, A., Teng, E. L., Duran, M., et al. (2018). Unveiling the role of the most impactful cardiovascular risk locus through haplotype editing. *Cell* 175, 1796–1810.e20. doi:10.1016/j.cell.2018.11.014
- Lopez, F., Sampedro, T., Llorente, J. L., Hermsen, M., and Alvarez-Marcos, C. (2017). Alterations of p14 (ARF), p15 (INK4b), and p16 (INK4a) genes in primary laryngeal squamous cell carcinoma. *Pathol. Oncol. Res.* 23, 63–71. doi:10.1007/s12253-016-0083-4
- Lyko, F. (2018). The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. *Nat. Rev. Genet.* 19, 81–92. doi:10.1038/nrg.2017.80
- Ma, W., Qiao, J., Zhou, J., Gu, L., and Deng, D. (2020). Characterization of novel LncRNA P14AS as a protector of ANRIL through AUF1 binding in human cells. *Mol. Cancer* 19, 42. doi:10.1186/s12943-020-01150-4
- Maggi, L. B., Jr., Winkler, C. L., Miceli, A. P., Apicelli, A. J., Brady, S. N., Kuchenreuther, M. J., et al. (2014). ARF tumor suppression in the nucleolus. *Biochim. Biophys. Acta*, 831–839. doi:10.1016/j.bbdis.2014.01.016
- Martin, N., Popov, N., Aguilo, F., O’Loughlin, A., Raguz, S., Snijders, A. P., et al. (2013). Interplay between Homeobox proteins and Polycomb repressive complexes in p16INK4a regulation. *EMBO J.* 32, 982–995. doi:10.1038/emboj.2013.37
- Matheu, A., Pantoja, C., Efeyan, A., Criado, L. M., Martin-Caballero, J., Flores, J. M., et al. (2004). Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. *Genes Dev.* 18, 2736–2746. doi:10.1101/gad.310304
- McHugh, D., and Gil, J. (2018). Senescence and aging: Causes, consequences, and therapeutic avenues. *J. Cell Biol.* 217, 65–77. doi:10.1083/jcb.201708092
- Mirzayans, R., Andrais, B., Hansen, G., and Murray, D. (2012). Role of p16(INK4A) in replicative senescence and DNA damage-induced premature senescence in p53-deficient human cells. *Biochem. Res. Int.*, 951574. doi:10.1155/2012/951574
- Montes, M., Nielsen, M. M., Maglieri, G., Jacobsen, A., Højfeldt, J., Agrawal-Singh, S., et al. (2015). The lncRNA MIR31HG regulates p16(INK4A) expression to modulate senescence. *Nat. Commun.* 6, 6967. doi:10.1038/ncomms7967
- Munger, K., Scheffner, M., Huibregtse, J. M., and Howley, P. M. (1992). Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. *Cancer Surv.* 12, 197–217.
- Muniz, L., Lazorthes, S., Delmas, M., Ouvrard, J., Aguirrebengoa, M., Trouche, D., et al. (2021). Circular ANRIL isoforms switch from repressors to activators of p15/CDKN2B expression during RAF1 oncogene-induced senescence. *RNA Biol.* 18, 404–420. doi:10.1080/15476286.2020.1812910
- Nakade, K., Pan, J., Yamasaki, T., Murata, T., Wasylyk, B., and Yokoyama, K. K. (2009). JDP2 (Jun Dimerization Protein 2)-deficient mouse embryonic fibroblasts are resistant to replicative senescence. *J. Biol. Chem.* 284, 10808–10817. doi:10.1074/jbc.M808333200
- Negishi, M., Saraya, A., Mochizuki, S., Helin, K., Koseki, H., and Iwama, A. (2010). A novel zinc finger protein Zfp277 mediates transcriptional repression of the Ink4a/arf locus through polycomb repressive complex 1. *PLoS One* 5, e12373. doi:10.1371/journal.pone.0012373
- Orlando, K. A., Nguyen, V., Raab, J. R., Walhart, T., and Weissman, B. E. (2019). Remodeling the cancer epigenome: Mutations in the SWI/SNF complex offer new therapeutic opportunities. *Expert Rev. Anticancer Ther.* 19, 375–391. doi:10.1080/14737140.2019.1605905
- Oruetxebarria, I., Venturini, F., Kekarainen, T., Houweling, A., Zuijderduijn, L. M., Mohd-Sarip, A., et al. (2004). P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. *J. Biol. Chem.* 279, 3807–3816. doi:10.1074/jbc.M309333200
- Papp, B., and Plath, K. (2011). Reprogramming to pluripotency: Stepwise resetting of the epigenetic landscape. *Cell Res.* 21, 486–501. doi:10.1038/cr.2011.28
- Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., et al. (2010). The C terminus of p53 binds the N-terminal domain of MDM2. *Nat. Struct. Mol. Biol.* 17, 982–989. doi:10.1038/nsmb.1872
- Prieto, L. I., and Baker, D. J. (2019). Cellular senescence and the immune system in cancer. *Gerontology* 65, 505–512. doi:10.1159/000500683
- Puvvula, P. K. (2019). LncRNAs regulatory networks in cellular senescence. *Int. J. Mol. Sci.* 20, E2615. doi:10.3390/ijms20112615
- Rayess, H., Wang, M. B., and Srivatsan, E. S. (2012). Cellular senescence and tumor suppressor gene p16. *Int. J. Cancer* 130, 1715–1725. doi:10.1002/ijc.27316
- Ribeiro, J. D., Morey, L., Mas, A., Gutierrez, A., Luis, N. M., Mejetta, S., et al. (2013). ZRF1 controls oncogene-induced senescence through the INK4-ARF locus. *Oncogene* 32, 2161–2168. doi:10.1038/ncr.2012.241
- Richly, H., Rocha-Viegas, L., Ribeiro, J. D., Demajo, S., Gundem, G., Lopez-Bigas, N., et al. (2010). Transcriptional activation of polycomb-repressed genes by ZRF1. *Nature* 468, 1124–1128. doi:10.1038/nature09574
- Roberts, C. W., and Orkin, S. H. (2004). The SWI/SNF complex--chromatin and cancer. *Nat. Rev. Cancer* 4, 133–142. doi:10.1038/nrc1273
- Robertson, K. D., and Jones, P. A. (1998). The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. *Mol. Cell Biol.* 18, 6457–6473. doi:10.1128/MCB.18.11.6457
- Rodriguez, C., Borgel, J., Court, F., Cathala, G., Forne, T., and Piette, J. (2010). CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locus. *Biochem. Biophys. Res. Commun.* 392, 129–134. doi:10.1016/j.bbrc.2009.12.159
- Romagosa, C., Simonetti, S., Lopez-Vicente, L., Mazo, A., Leonart, M. E., Castellvi, J., et al. (2011). p16(Ink4a) overexpression in cancer: A tumor suppressor gene associated with senescence and high-grade tumors. *Oncogene* 30, 2087–2097. doi:10.1038/ncr.2010.614
- Russo, A. A., Tong, L., Lee, J. O., Jeffrey, P. D., and Pavletich, N. P. (1998). Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. *Nature* 395, 237–243. doi:10.1038/26155
- Sang, Y., Tang, J., Li, S., Li, L., Tang, X., Cheng, C., et al. (2016). LncRNA PANDAR regulates the G1/S transition of breast cancer cells by suppressing p16(INK4A) expression. *Sci. Rep.* 6, 22366. doi:10.1038/srep22366
- Sevenet, N., Sheridan, E., Amram, D., Schneider, P., Handgretinger, R., and Delattre, O. (1999). Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. *Am. J. Hum. Genet.* 65, 1342–1348. doi:10.1086/302639
- Sharpless, N. E. (2005). INK4a/ARF: A multifunctional tumor suppressor locus. *Mutat. Res.* 576, 22–38. doi:10.1016/j.mrfmmm.2004.08.021
- Sherr, C. J. (2012). Ink4-Arf locus in cancer and aging. *Wiley Interdiscip. Rev. Dev. Biol.* 1, 731–741. doi:10.1002/wdev.40
- Sherr, C. J. (2001). The INK4a/ARF network in tumour suppression. *Nat. Rev. Mol. Cell Biol.* 2, 731–737. doi:10.1038/35096061
- Shields, B. J., Jackson, J. T., Metcalf, D., Shi, W., Huang, Q., Garnham, A. L., et al. (2016). Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a. *Genes Dev.* 30, 78–91. doi:10.1101/gad.268425.115
- Sreeramaneni, R., Chaudhry, A., McMahon, M., Sherr, C. J., and Inoue, K. (2005). Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. *Mol. Cell Biol.* 25, 220–232. doi:10.1128/MCB.25.1.220-232.2005
- Su, W., Hong, L., Xu, X., Huang, S., Herpai, D., Li, L., et al. (2018). miR-30 disrupts senescence and promotes cancer by targeting both p16(INK4A) and DNA damage pathways. *Oncogene* 37, 5618–5632. doi:10.1038/s41388-018-0358-1
- Swigut, T., and Wysocka, J. (2007). H3K27 demethylases, at long last. *Cell* 131, 29–32. doi:10.1016/j.cell.2007.09.026
- Tsujimoto, H., Hagiwara, A., Sugihara, H., Hattori, T., and Yamagishi, H. (2002). Promoter methylations of p16INK4a and p14ARF genes in early and advanced gastric cancer. Correlations of the modes of their occurrence with histologic type. *Pathol. Res. Pract.* 198, 785–794. doi:10.1078/0344-0338-00337
- Tzatsos, A., Pfau, R., Kampranis, S. C., and Tschlis, P. N. (2009). Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus. *Proc. Natl. Acad. Sci. U. S. A.* 106, 2641–2646. doi:10.1073/pnas.0813139106

- van Deursen, J. M. (2014). The role of senescent cells in ageing. *Nature* 509, 439–446. doi:10.1038/nature13193
- Visel, A., Zhu, Y., May, D., Afzal, V., Gong, E., Attanasio, C., et al. (2010). Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. *Nature* 464, 409–412. doi:10.1038/nature08801
- Wade, M., Wang, Y. V., and Wahl, G. M. (2010). The p53 orchestra: Mdm2 and Mdmx set the tone. *Trends Cell Biol.* 20, 299–309. doi:10.1016/j.tcb.2010.01.009
- Wang, W., Pan, K., Chen, Y., Huang, C., and Zhang, X. (2012). The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression. *Nucleic Acids Res.* 40, 981–995. doi:10.1093/nar/gkr818
- Wang, W., Qin, J. J., Voruganti, S., Nag, S., Zhou, J., and Zhang, R. (2015). Polycomb group (PcG) proteins and human cancers: Multifaceted functions and therapeutic implications. *Med. Res. Rev.* 35, 1220–1267. doi:10.1002/med.21358
- Wang, X., Pan, L., Feng, Y., Wang, Y., Han, Q., Han, L., et al. (2008). P300 plays a role in p16(INK4a) expression and cell cycle arrest. *Oncogene* 27, 1894–1904. doi:10.1038/sj.onc.1210821
- Watanabe, T., Nakamura, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2001). Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. *Acta Neuropathol.* 101, 185–189. doi:10.1007/s004010000343
- Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., and Bar-Sagi, D. (1999). Nucleolar Arf sequesters Mdm2 and activates p53. *Nat. Cell Biol.* 1, 20–26. doi:10.1038/8991
- Wilson, B. G., and Roberts, C. W. (2011). SWI/SNF nucleosome remodellers and cancer. *Nat. Rev. Cancer* 11, 481–492. doi:10.1038/nrc3068
- Wu, D., Tan, H., Su, W., Cheng, D., Wang, G., Wang, J., et al. (2022). MZF1 mediates oncogene-induced senescence by promoting the transcription of p16(INK4A). *Oncogene* 41, 414–426. doi:10.1038/s41388-021-02110-y
- Wu, J., Xue, L., Weng, M., Sun, Y., Zhang, Z., Wang, W., et al. (2007). Sp1 is essential for p16 expression in human diploid fibroblasts during senescence. *PLoS One* 2, e164. doi:10.1371/journal.pone.0000164
- Xiang, Y., Zhu, Z., Han, G., Lin, H., Xu, L., and Chen, C. D. (2007). JMJD3 is a histone H3K27 demethylase. *Cell Res.* 17, 850–857. doi:10.1038/cr.2007.83
- Yan, M., Yang, X., Wang, H., and Shao, Q. (2018). The critical role of histone lysine demethylase KDM2B in cancer. *Am. J. Transl. Res.* 10, 2222–2233.
- Yap, K. L., Li, S., Munoz-Cabello, A. M., Raguz, S., Zeng, L., Mujtaba, S., et al. (2010). Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. *Mol. Cell* 38, 662–674. doi:10.1016/j.molcel.2010.03.021
- Yu, G. W., Rudiger, S., Vepriyev, D., Freund, S., Fernandez-Fernandez, M. R., and Fersht, A. R. (2006). The central region of HDM2 provides a second binding site for p53. *Proc. Natl. Acad. Sci. U. S. A.* 103, 1227–1232. doi:10.1073/pnas.0510343103
- Zhang, G. G., Xu, Y., Zou, C., Tang, Y., Lu, J., Gong, Z., et al. (2019). Long noncoding RNA ARHGAP27P1 inhibits gastric cancer cell proliferation and cell cycle progression through epigenetically regulating p15 and p16. *Aging (Albany NY)* 11, 9090–9110. doi:10.18632/aging.102377
- Zhang, X., Liu, L., Yuan, X., Wei, Y., and Wei, X. (2019). JMJD3 in the regulation of human diseases. *Protein Cell* 10, 864–882. doi:10.1007/s13238-019-0653-9
- Zhang, Y., Hyle, J., Wright, S., Shao, Y., Zhao, X., Zhang, H., et al. (2019). A cis-element within the ARF locus mediates repression of p16 (INK4A) expression via long-range chromatin interactions. *Proc Natl Acad Sci U S A* 116, 26644–26652. doi:10.1073/pnas.1909720116
- Zhao, W., Li, Q., Ayers, S., Gu, Y., Shi, Z., Zhu, Q., et al. (2013). Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. *Cell* 152, 1037–1050. doi:10.1016/j.cell.2013.02.006
- Zheng, Y., Devitt, C., Liu, J., Mei, J., and Skapek, S. X. (2013). A distant, cis-acting enhancer drives induction of Arf by Tgfb β in the developing eye. *Dev. Biol.* 380, 49–57. doi:10.1016/j.ydbio.2013.05.003
- Zheng, Y., Zhao, Y. D., Gibbons, M., Abramova, T., Chu, P. Y., Ash, J. D., et al. (2010). Tgfbeta signaling directly induces Arf promoter remodeling by a mechanism involving Smads 2/3 and p38 MAPK. *J. Biol. Chem.* 285, 35654–35664. doi:10.1074/jbc.M110.128959
- Zhou, Y. G., Sun, F., and Zhou, Y. F. (2020). Low expression of lncRNA TUBA4B promotes proliferation and inhibits apoptosis of colorectal cancer cells via regulating P15 and P16 expressions. *Eur. Rev. Med. Pharmacol. Sci.* 24, 3023–3029. doi:10.26355/eurrev_202003_20666
- Zhu, J., Woods, D., McMahon, M., and Bishop, J. M. (1998). Senescence of human fibroblasts induced by oncogenic Raf. *Genes Dev.* 12, 2997–3007. doi:10.1101/gad.12.19.2997